Alternatively, in refractory B-cell lymphoma with impaired apoptotic machinery, the combination of BTZ and cell-cycle specific chemotherapy agents or novel cell cycle inhibitors may improve outcomes for this subset of patients. Here, CASC3 is linked to B-cell non-Hodgkin lymphoma.